Innovative Early Prostate Cancer Detection
NucleoBio's Prostac® is a straightforward molecular blood test that facilitates early, precise prostate cancer detection, aiming to save men's lives and improve their quality of life.
Photo credit: Shutterstock.com / LightField Studio
Prostac®
Pre-FDA approved, Prostac® is a patented and straightforward molecular-based blood test that facilitates the early detection** of prostate cancer with near 100% precision.
Prostac® replaces the Prostate-Specific Antigen (PSA) test, and the additional expensive, intrusive diagnostic tests presently needed to more accurately diagnose prostate cancer, and helps eliminate unnecessary, and often harmful, overtreatments.
Prostac® takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.
** Note: Prostac is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.
Prostac® Products
Prostac® Diagnostic Lab Test
This test can be performed at a Physicians' office or healthcare facility. The Prostac® Diagnostic Lab Test analyzes a drawn blood sample to:
-
Detect if a man has prostate cancer and the aggressiveness of the cancer if detected.
-
Identify a man's predisposition to developing prostate cancer.
-
Categorize the diagnosed prostate cancer into a distinct risk group ranging from indolent to aggressive castration-resistant.
-
Identify genetically precise, personalized medical treatments based on the patient’s risk group and genetic factors.
Prostac® "Point of Service" Test (Future)
The Prostac® “Point of Service” test is an inexpensive microfluidic or lateral flow assay that analyzes a man’s urine to:
-
Detect possible prostate cancer.
-
Regularly test a man who has a predisposition to prostate cancer or who has been diagnosed with low grade (indolent) prostate cancer.
A “+” test would refer the patient back to his Doctor for the Prostac® Diagnostic Lab Test.